Prestin Protein Identified as Potential Tinnitus Biomarker

For the roughly 15 percent of the global population living with tinnitus, the persistent sensation of ringing or phantom sounds is a reality that has long defied objective diagnosis.

Until now, clinicians have relied entirely on patient self-reporting to identify the condition, leaving doctors unsure of what actually occurs within the body. A new study published in Otolaryngology – Head and Neck Surgery suggests that this diagnostic uncertainty may finally be narrowing.

Scientists have identified a potential biological signature for tinnitus located directly in the blood. Research involving 82 adults—split evenly between those experiencing tinnitus and those who are not—revealed that a specific protein, known as prestin, appears to be linked to the condition. According to the study, participants with tinnitus exhibited blood concentrations of this protein that were approximately 50 percent higher than those in the control group.

Prestin is a motor protein nestled within the membranes of outer hair cells in the cochlea, the spiral-shaped cavity of the inner ear. Its primary function is to amplify sounds, serving as a critical component for sensitive hearing. Because previous research has established a link between prestin and hearing damage, its role in tinnitus has become a focal point for researchers investigating cochlear health.

The implications of this finding extend to how we understand trauma and chemical exposure in the ear. Past studies have shown that prestin levels are susceptible to fluctuations caused by age, noise exposure, and hearing loss.

Research indicates that high doses of aspirin affect the protein, which can disrupt cochlear function and induce hearing problems. As noted in a previous study, these changes suggest that the protein acts as a potential biomarker for cochlear injury.

Kourosh Parham, an otolaryngologist at the University of Connecticut, views these results as a vital step forward. We now have proof-of-concept that an ear protein may play a central role in the development and management of tinnitus, Parham stated. The team behind this research hopes that establishing prestin as a biomarker could eventually lead to the development of targeted drugs to manage the condition.

Our work now says there is promise in using prestin as a biomarker for tinnitus. This is our first step to developing drugs to help manage tinnitus, says Kourosh Parham.

Despite the promise of these findings, the path to a standard clinical test remains complex. The researchers acknowledge that this was a small, observational study, and the current data does not confirm that elevated prestin levels directly trigger the onset of tinnitus. Rather, the two are linked in a way that warrants further investigation.

A separate diagnostic accuracy analysis conducted as part of the study indicated that the biomarker cannot yet be used to reliably diagnose tinnitus in a clinical setting.

The researchers suggest that this limitation may stem from the fact that some participants likely suffered from non-cochlear tinnitus—a form of the condition caused by factors other than prestin abnormalities. Future research will be necessary to determine which specific patients might benefit from a blood-based diagnostic test and how other contributing factors interact with this protein signature.